Tiziana Life Sciences (TLSA) aims to deliver Foralumab, the world’s first intranasal anti-CD3 immunotherapy, as a disease-modifying, at-home treatment that halts neuroinflammation and progression in currently incurable conditions—starting with non-active secondary progressive MS (SPMS), where it has shown up to 50% reduction in brain microglia activation via PET imaging in Phase 2a, then expanding to ALS, Alzheimer’s, multiple system atrophy (MSA), and spinal cord injury. Unlike systemic injectables or infusions that suppress immunity body-wide with side effects and limited brain penetration, Foralumab’s nasal spray targets T-cells locally in the CNS, inducing regulatory T-cells (Tregs) to restore immune balance without broad immunosuppression—potentially stopping disability progression in 500,000+ SPMS patients, extending functional independence in ALS, and slowing cognitive decline in early Alzheimer’s. Backed by FDA fast-track, orphan designations, and non-dilutive grants (DoD, ALS Association), TLSA plans Phase 3 launches by 2027, global approvals by 2029, and peak sales exceeding $2 billion annually across indications by 2030, transforming neuroimmunology from symptom management to true disease modification with a simple, patient-friendly spray.